Allied BioScience
Developing, producing, and distributing unique, transparent, and durable antimicrobial surface coatings that economically, effectively, and continuously diminish the microbial burden and reduce the incidence of bacterial, viral, and fungal disease.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
N/A | Series C | ||
| Total Funding | 000k | ||
Allied BioScience, founded in 2005, operates in the biotechnology sector, focusing on the development of antimicrobial coating products designed to mitigate the spread of infectious diseases in public spaces. The company was established by Nick Dallas, an entrepreneur with a background in health technology. Michael Ruley, who has a history of leadership in the telecommunications industry, serves as the CEO.
The firm's core business revolves around creating long-lasting, continuously active antimicrobial coatings that reduce the presence of pathogens on both hard and soft surfaces. Unlike traditional disinfectants that offer temporary protection, these coatings are engineered to provide durable, ongoing protection against viruses and bacteria between cleanings. Revenue is generated through B2B sales of its flagship antimicrobial coatings, often through bulk orders and customizable service agreements tailored to specific sectors. The company markets its products in North America, Europe, and parts of Asia, serving a diverse client base that includes healthcare facilities, educational institutions, commercial businesses, and sports facilities.
A key product is SurfaceWise™, a transparent, odorless, and non-tacky bacteriostatic surface coating. In November 2018, Allied BioScience received an approved label from the U.S. Environmental Protection Agency (EPA) for SurfaceWise™, which inhibits the growth of bacteria, fungi, and algae. The company later developed SurfaceWise2™, which received emergency use authorization from the EPA during the COVID-19 pandemic to protect against SARS-CoV-2. This authorization, however, was later revoked in July 2021 due to concerns about the product's real-world effectiveness and marketing claims, leading to a Stop Sale, Use or Removal Order and a subsequent settlement with the EPA in March 2022.
The company has raised a total of $10.7 million in funding over several rounds, with investors including Lydia Partners, Capital7, Alternative Investment Management, and VentureLabs. This capital is intended to support global expansion, further regulatory approvals, and the development of next-generation products beyond surface coatings. In February 2021, Allied BioScience expanded its headquarters in Plano, Texas, to accommodate a growing team and to support increased sales and product diversification. Keywords: antimicrobial coatings, surface protection, infection prevention, biotechnology, pathogen control, long-lasting disinfectant, surface sanitizer, public health solutions, healthcare sanitation, commercial hygiene, SurfaceWise, EPA registered, institutional cleaning, microbial bioburden, cleaner environments, pathogen reduction, surface technology, health technology, antimicrobial technology, infection control products